Visual Outcomes
Best outcome measures for NF1-associated optic pathway gliomas, including psychophysical vision, ophthalmologic elements, and quality of life.
Leadership
About This Group
The goal of the visual outcome working group is to define the best outcome measures for use in clinical trials of NF1 associated optic pathway gliomas (OPG). Our group assesses psychophysical components of vision, other ophthalmologic elements affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at consensus-based, evidence-driven recommendations.
Current group co-leaders: Rob Avery, MD and Michael Fisher, MD Past group leader: Michael Fisher, MD
Ongoing consensus-based, evidence-driven recommendations for OPG clinical trials.
Additional Information
No additional sections yet.
Working Group Snapshot & Focus Updates
No snapshot update posted yet.
Publications & References
Functional outcome measures for NF1-associated optic pathway glioma clinical trials
Fisher MJ, Avery RA, Allen JC, et al. Neurology. 2013;81(21 Suppl 1):S15–S22.
Documents & Resources
No documents uploaded yet.
Join or Contact This Group
Membership is open to all interested parties. Meetings are primarily held by teleconference.
Express Interest